Quantx Biosciences closed an $85 million Series B to advance two oral immunology programs—one targeting STAT6 and another IL‑17—into clinical testing, accelerating candidate IND timelines. The financing positions the company to start human studies and expand its discovery platform for small‑molecule immunomodulators. Separately, Anterior raised $40 million to expand an AI platform that automates administrative prior‑authorization work for health plans, aiming to shorten care-approval timelines from weeks to minutes. Together, the financings reflect continued investor appetite across both therapeutic R&D and health‑tech tools that aim to reduce friction in care delivery.